Summary

Genetic factors may be responsible for some of the inter-individual variability in dabigatran exposure, according to findings from the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY] Genetics study. The RE-LY trial demonstrated that dabigatran 150 mg BID was superior to warfarin, while the 110 mg dose was noninferior to warfarin in the reduction of stroke in patients with atrial fibrillation [Connolly SJ et al. N Engl J Med 2009].